Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2017

View Archived Issues

Lung Therapeutics completes series B financing

Mustang Bio enters CAR T therapy agreement with City of Hope

Roivant Sciences launches new company

Novartis discovers novel MALT1 inhibitors

New MAPK 1 inhibtors patented by AstraZeneca

Neuform Pharmaceuticals divulges new PI3Kdelta inhibitors

Actelion identifies prostanoid EP2/EP4 receptor antagonists

Bristol-Myers Squibb patents TYK2 inhibitors

Merck & Co. discloses novel HIV integrase inhibitors

Mateon Therapeutics' OXi-4503 awarded FDA fast track designation

Synlogic completes first phase of collaboration with AbbVie

Teva reports results from second phase III HALO study of fremanezumab

First patient dosed in phase I/II study of ARQ-092

InCarda Therapeutics announces topline data from phase I study of InRhythm

Avanir Pharmaceuticals begins enrolling patients in phase II study of AVP-786

BlackThorn and Mindstrong Health enter biomarker collaboration

FDA gives fast track designation to Calithera Biosciences' CB-839

ADMA completes acquisition of Biotest Pharmaceuticals' therapy business unit

First data for the antibody-drug conjugate ABBV-221 in solid tumors

Novel M. tuberculosis dihydrofolate reductase inhibitor identified for in vivo testing

Shire to transfer IND for phase II/III study of alpha-1 antitrypsin i.v. to Kamada

Caris and Foundation Medicine announce collaborations with NCI and ECOG-ACRIN

Lilly presents detailed results from MONARCH2 trial of abemaciclib in advanced breast cancer

Cellceutix changes its name to Innovation Pharmaceuticals

First clinical data for AGEN-1884 in advanced solid malignancies

Actelion gives an update on the phase III IMPACT program

Tiziana Life Sciences discontinues its Bcl-3 preclinical development program

APHINITY trial: pertuzumab plus herceptin in early adjuvant breast cancer

Symproic tablets launched in Japan for the treatment of opioid-induced constipation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...